GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...

Asian equities were mostly lower overnight on increased trade rhetoric and the hiking of tariffs on Canada and a litany of ...